Abstract:LESSONS LEARNED:The NEO-CLASSIC study provided valuable insight for the clinical efficacy and tolerability profiles of perioperative chemotherapy with oxaliplatin and capecitabine, plus gastrectomy, in patients with localized resectable gastric cancer.The study was designed to explore the potential survival benefits of an eight-cycle, perioperative oxaliplatin and capecitabine (XELOX) schedule in the above-mentioned setting and to explore the feasibility of prolonging the cycles of preoperative chemotherapy. The projected endpoint was not met.BACKGROUND:This multicenter, open-label study (NEO-CLASSIC) evaluated the efficacy and safety of oxaliplatin and capecitabine (XELOX), plus D2 gastrectomy, in localized resectable gastric cancer.METHODS:Patients aged 18-75 years with histologically-confirmed gastric adenocarcinoma (stage T2-4a/N+M0) were given eight cycles of XELOX (four preoperatively, four postoperatively). Each 3-week cycle comprised capecitabine 1,000 mg/m2 twice daily on days 1-14 and oxaliplatin 130 mg/m2 on day 1. Curative D2 gastrectomy was scheduled 2-4 weeks after the last preoperative cycle. The primary objective of the study was to determine the objective response rate (ORR) of XELOX in the preoperative setting. Sample size was calculated by assuming that a minimum of 47 cases would be required to increase the ORR by 15% (from 40% to 55%). With an estimated 10% dropout rate, 55 patients would have to be recruited.RESULTS:Fifty-five patients were enrolled, and one was excluded because of screening failure. R0 resections were achieved in 45 of 54 intent-to-treat patients (83.3%), and four patients received R1 resections (Fig. 1). There were no complete responses, 27 (50.0%) partial responses, 22 cases (40.7%) of stable disease, and 4 (7.4%) of progressive disease. The objective response rate was 50.0%. Median follow-up was 52.97 months; 30 patients (55.6%) had disease progression (Table 1), and median progression-free survival was 20.10 (95% confidence interval: 4.31-35.89) months; median overall survival was 30.77 months (95% confidence interval was not yet available) (Fig. 2). Fifty-four patients completed 209 cycles of preoperative chemotherapy; 42 patients received 133 cycles of postoperative chemotherapy (Table 3). The rate of grade 3-4 adverse events was 8.5% (29/342 cycles); the most frequent events were neutropenia (9/342 cycles) and leukopenia (4/342 cycles).CONCLUSION:These findings suggest that combination therapy with capecitabine and oxaliplatin as perioperative chemotherapy, followed by D2 gastrectomy, is effective and safe in late-stage, locally advanced gastric cancer. Although enrollment exceeded the 47 patients required to identify an increase in the ORR by 15% (from 40% to 55%), results did not meet the primary endpoint.

Outcomes of a Phase II Study of Intraperitoneal Paclitaxel plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases

A Phase Ii, Open-Label, Multicenter, Prospective Study of Paclitaxel Plus Capecitabine with Subsequent Capecitabine Maintenance Therapy As First-Line Treatment for Metastatic or Recurrent Gastric Cancer

144O Comparison of Efficacy and Safety of Paclitaxel and Capecitabine Followed by Capecitabine As Maintenance Therapy Versus Cisplatin and Capecitabine Therapy for Advanced Gastric Cancer: a Multicentre, Randomised, Active-Controlled Phase III Study

A Multicenter, Phase II Study of Trastuzumab Plus Capecitabine and Oxaliplatin (XELOX) As First-Line Chemotherapy for HER2-positive Advanced Gastric Cancer: Update Results of Efficacy and Toxicity.

Oxaliplatin Plus S-1 with Intraperitoneal Paclitaxel for the Treatment of Chinese Advanced Gastric Cancer with Peritoneal Metastases

The Multicenter, Phase Ii Prospective Study of Paclitaxel Plus Capecitabine As First-Line Chemotherapy in Advanced Gastric Carcinoma

A Multicenter, Randomized Trial Comparing Efficacy and Safety of Paclitaxel/capecitabine and Cisplatin/capecitabine in Advanced Gastric Cancer

Randomized Phase II Study of TX Followed by XELOX Versus the Reverse Sequence for Chemo-Naive Patients with Metastatic Gastric Cancer

A Phase Ii Study of Triweekly Paclitaxel and Capecitabine Combination Therapy in Patients with Fluoropyrimidine-Platinum-Resistant Metastatic Gastric Adenocarcinoma

A Phase II Trial of Xeloda and Oxaliplatin (XELOX) Neo-Adjuvant Chemotherapy Followed by Surgery for Advanced Gastric Cancer Patients with Para-Aortic Lymph Node Metastasis

Adjuvant Capecitabine and Oxaliplatin Vs. Capecitabine and Paclitaxel in Gastric Cancer Patients after D2 Gastrectomy

A Phase Ii Study of Biweekly Oxaliplatin and S-1(Sox) As First-Line Combination Therapy in Patients with Advanced Gastric Cancer.

Study of SOX combined with intraperitoneal high‐dose paclitaxel in gastric cancer with synchronous peritoneal metastasis: A phase II single‐arm clinical trial

Phase II Trial of XELOX As First-Line Treatment for Patients with Advanced Gastric Cancer

Oxaliplatin Plus Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma in Combination with D2 Gastrectomy: NEO-CLASSIC Study.

Short-term outcomes of a phase II trial of perioperative capecitabine plus oxaliplatin therapy for advanced gastric cancer with extensive lymph node metastases (OGSG1701)

Oxaliplatin Plus Capecitabine (XELOX) in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma in Combination with D2 Gastrectomy (NEO-CLASSIC).

Long-Term Outcome of Oxaliplatin and Capecitabine (XELOX) Concomitant with Neoadjuvant Radiotherapy and Extended to the Resting Period in High Risk Locally Advanced Rectal Cancer.

A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

Phase Ii Clinical Trial Of Xelox As First Line Treatment For Patients With Unresectable Or Metastatic Gastric Cancer

Capecitabine Plus Paclitaxel Induction Treatment in Gastric Cancer Patients with Liver Metastasis: a Prospective, Uncontrolled, Open-Label Phase II Clinical Study.